{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T11:37:55Z","timestamp":1792496275774,"version":"4.5.0"},"reference-count":231,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T00:00:00Z","timestamp":1690243200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ejca.2023.113252","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T21:26:17Z","timestamp":1690493177000},"page":"113252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":108,"special_numbering":"C","title":["European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment\u2013Update 2023"],"prefix":"10.1016","volume":"193","author":[{"given":"Alexander J.","family":"Stratigos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8530-780X","authenticated-orcid":false,"given":"Claus","family":"Garbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4832-3410","authenticated-orcid":false,"given":"Clio","family":"Dessinioti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste","family":"Lebbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"van Akkooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Bataille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5478-9826","authenticated-orcid":false,"given":"Lars","family":"Bastholt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Dreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2279-6906","authenticated-orcid":false,"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Concetta","family":"Fargnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1007-7883","authenticated-orcid":false,"given":"Ana Maria","family":"Forsea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine A.","family":"Harwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Hauschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Hoeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidija","family":"Kandolf-Sekulovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole WJ","family":"Kelleners-Smeets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7193-0964","authenticated-orcid":false,"given":"Aimilios","family":"Lallas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8019-1577","authenticated-orcid":false,"given":"Ulrike","family":"Leiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Malvehy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"del Marmol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1301-7974","authenticated-orcid":false,"given":"David","family":"Moreno-Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Pellacani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketty","family":"Peris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6500-3507","authenticated-orcid":false,"given":"Philippe","family":"Saiag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2308-0982","authenticated-orcid":false,"given":"Luca","family":"Tagliaferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrto","family":"Trakatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Ioannides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7878-4955","authenticated-orcid":false,"given":"Iris","family":"Zalaudek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Arenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.M.","family":"Eggermont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"R\u00f6cken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Grob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Lorigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2023.113252_bib1","unstructured":"Howick\u00a0J,\u00a0Chalmers\u00a0I,\u00a0Glasziou\u00a0P,\u00a0Greenhalgh\u00a0T,\u00a0Heneghan\u00a0C,\u00a0Liberati\u00a0A, et al. The Oxford levels of evidence 2, https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/ocebm-levels-of-evidence [accessed July 17,\u00a02022]: Oxford center for evidence-based medicine."},{"key":"10.1016\/j.ejca.2023.113252_bib2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/bjd.19621","article-title":"British Association of Dermatologists guidelines for the management of people with cutaneous squamous cell carcinoma 2020","volume":"184","author":"Keohane","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2023.113252_bib3","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1159\/000524460","article-title":"A sensitivity meta-analysis of disease-specific death in localized cutaneous squamous cell carcinoma","volume":"238","author":"Dessinioti","year":"2022","journal-title":"Dermatology"},{"key":"10.1016\/j.ejca.2023.113252_bib4","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1111\/jdv.16268","article-title":"Treatment of keratinocyte carcinoma in elderly patients\u2013a review of the current literature","volume":"34","author":"Leus","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2023.113252_bib5","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ejca.2021.08.018","article-title":"Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma","volume":"157","author":"Baggi","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.113252_bib6","article-title":"Cemiplimab in an elderly frail population of patients with locally advanced or metastatic cutaneous squamous cell carcinoma: a single-center real-life experience from Italy","volume":"11","author":"Strippoli","year":"2021","journal-title":"Front\u00a0Oncol"},{"key":"10.1016\/j.ejca.2023.113252_bib7","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1007\/s00432-022-04246-0","article-title":"Anti-PD-1 for the treatment of advanced cutaneous squamous cell carcinoma in elderly patients: a French multicenter retrospective survey","volume":"149","author":"Samaran","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113252_bib8","first-page":"999","article-title":"Local surgical treatment of cutaneous squamous cell carcinoma: deficits and controversies in the literature","volume":"17","author":"Breuninger","year":"2019","journal-title":"J\u00a0Ger\u00a0Soc\u00a0Dermatol: JDDG"},{"key":"10.1016\/j.ejca.2023.113252_bib9","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1111\/bjd.17510","article-title":"The illusion of conventional histological resection margin control","volume":"180","author":"van Delft","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2023.113252_bib10","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jaad.2017.10.007","article-title":"Guidelines of care for the management of cutaneous squamous cell carcinoma","volume":"78","author":"Alam","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.113252_bib11","doi-asserted-by":"crossref","first-page":"f6153","DOI":"10.1136\/bmj.f6153","article-title":"Interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies","volume":"347","author":"Lansbury","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.ejca.2023.113252_bib12","first-page":"706","article-title":"Risk factors for positive margins after wide local excision of cutaneous squamous cell carcinoma","volume":"29","author":"Stewart","year":"2018","journal-title":"J Dermatol\u00a0Treat"},{"key":"10.1016\/j.ejca.2023.113252_bib13","first-page":"ed2023","article-title":"National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology","volume":"version 1","author":"Schmults","year":"2023","journal-title":"Squamous Cell Skin Cancer"},{"key":"10.1016\/j.ejca.2023.113252_bib14","first-page":"400","article-title":"S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma (cSCC) - short version, part 2: epidemiology, surgical and systemic treatment of cSCC, follow-up, prevention and occupational disease","volume":"18","author":"Leiter","year":"2020","journal-title":"J\u00a0Ger\u00a0Soc\u00a0Dermatol: JDDG"},{"key":"10.1016\/j.ejca.2023.113252_bib15","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/PAP.0000000000000157","article-title":"Cutaneous squamous cell carcinoma: review of the eighth edition of the American Joint Committee on cancer staging guidelines, prognostic factors, and histopathologic variants","volume":"24","author":"Motaparthi","year":"2017","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.ejca.2023.113252_bib16","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0190-9622(92)70178-I","article-title":"Surgical margins for excision of primary cutaneous squamous cell carcinoma","volume":"27","author":"Brodland","year":"1992","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.113252_bib17","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/01.PRS.0000067479.77859.31","article-title":"Excision margins for non-melanotic skin cancer","volume":"112","author":"Thomas","year":"2003","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.ejca.2023.113252_bib18","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1159\/000444051","article-title":"Squamocellular carcinoma of the skin: clinicopathological features predicting the involvement of the surgical margins and review of the literature","volume":"232","author":"Ribero","year":"2016","journal-title":"Dermatology"},{"issue":"Suppl 5","key":"10.1016\/j.ejca.2023.113252_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-3083.2011.04296.x","article-title":"Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma and precursor lesions","volume":"25","author":"Bonerandi","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2023.113252_bib20","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1177\/1203475415582318","article-title":"Non-melanoma skin cancer in canada chapter 5: management of squamous cell carcinoma","volume":"19","author":"Sapijaszko","year":"2015","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.ejca.2023.113252_bib21","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejca.2020.01.008","article-title":"European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: part 2. Treatment","volume":"128","author":"Stratigos","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.113252_bib22","doi-asserted-by":"crossref","first-page":"e288","DOI":"10.1111\/1346-8138.15889","article-title":"Japanese dermatological association guidelines: outlines of guidelines for cutaneous squamous cell carcinoma 2020","volume":"48","author":"Ansai","year":"2021","journal-title":"J Dermatol"},{"key":"10.1016\/j.ejca.2023.113252_bib23","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1097\/DSS.0000000000003606","article-title":"Rate and characteristics of incompletely excised cutaneous squamous cell carcinoma: a dermatological daily practice multicenter prospective cohort study","volume":"48","author":"van Lee","year":"2022","journal-title":"Dermatol Surg"},{"issue":"Suppl 1","key":"10.1016\/j.ejca.2023.113252_bib24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/jdv.17531","article-title":"Overview of guideline recommendations for the management of high-risk and advanced cutaneous squamous cell carcinoma","volume":"36","author":"Dessinioti","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2023.113252_bib25","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0007-1226(03)00028-6","article-title":"Multiprofessional guidelines for the management of the patient with primary cutaneous squamous cell carcinoma","volume":"56","author":"Motley","year":"2003","journal-title":"Br J Plast Surg"},{"key":"10.1016\/j.ejca.2023.113252_bib26","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.bjps.2012.12.016","article-title":"Guidelines for the excision of cutaneous squamous cell cancers in the United Kingdom: the best cut is the deepest","volume":"66","author":"Khan","year":"2013","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"10.1016\/j.ejca.2023.113252_bib27","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1017\/S0022215116000554","article-title":"Non-melanoma skin cancer: United Kingdom National Multidisciplinary Guidelines","volume":"130","author":"Newlands","year":"2016","journal-title":"J Laryngol Otol"},{"key":"10.1016\/j.ejca.2023.113252_bib28","first-page":"1088","article-title":"Narrower clinical margin in high or very high-risk squamous cell carcinoma: a retrospective, multicenter study of 1,000 patients","volume":"20","author":"Baba","year":"2022","journal-title":"J\u00a0Ger\u00a0Soc\u00a0Dermatol: JDDG"},{"key":"10.1016\/j.ejca.2023.113252_bib29","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/bjd.17188","article-title":"Recurrence rates of cutaneous squamous cell carcinoma of the head and neck after Mohs micrographic surgery versus\u00a0standard excision: a retrospective cohort study","volume":"181","author":"van Lee","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2023.113252_bib30","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/0190-9622(92)70144-5","article-title":"Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection","volume":"26","author":"Rowe","year":"1992","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.113252_bib31","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1111\/ced.15187","article-title":"A review of Mohs micrographic surgery for skin cancer. Part 3: squamous cell carcinoma","volume":"47","author":"Hunt","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.ejca.2023.113252_bib32","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1468-3083.2007.02187.x","article-title":"A confusing world: what to call histology of three-dimensional tumour margins?","volume":"21","author":"Moehrle","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2023.113252_bib33","first-page":"942","article-title":"S1 guideline: microscopically controlled surgery (MCS)","volume":"13","author":"Loser","year":"2015","journal-title":"J\u00a0Ger\u00a0Soc\u00a0Dermatol: JDDG"},{"key":"10.1016\/j.ejca.2023.113252_bib34","first-page":"1080","article-title":"The Muffin technique\u2013an alternative to Mohs' micrographic surgery","volume":"4","author":"Mohrle","year":"2006","journal-title":"J\u00a0Ger\u00a0Soc\u00a0Dermatol: JDDG"},{"issue":"2","key":"10.1016\/j.ejca.2023.113252_bib35","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jaad.2015.04.027","article-title":"Ex vivo fluorescence confocal microscopy in conjunction with Mohs micrographic surgery for cutaneous squamous cell carcinoma","volume":"73","author":"Longo","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.113252_bib36","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jaad.2005.02.059","article-title":"Cutaneous squamous cell carcinoma treated with Mohs micrographic surgery in Australia I. Experience over 10 years","volume":"53","author":"Leibovitch","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.113252_bib37","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1111\/j.1524-4725.2010.01576.x","article-title":"Mohs surgery is effective for high-risk cutaneous squamous cell carcinoma","volume":"36","author":"Pugliano-Mauro","year":"2010","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.ejca.2023.113252_bib38","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/jid.2012.403","article-title":"Tumour recurrence 5 years after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma","volume":"133","author":"Chren","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ejca.2023.113252_bib39","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jaad.2018.09.015","article-title":"Clinical outcomes in high-risk squamous cell carcinoma patients treated with Mohs micrographic surgery alone","volume":"80","author":"Marrazzo","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.113252_bib40","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaad.2019.06.1303","article-title":"Long-term clinical outcomes of patients with invasive cutaneous squamous cell carcinoma treated with Mohs micrographic surgery: a 5-year, multicenter, prospective cohort study","volume":"82","author":"Tschetter","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.113252_bib41","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.jaad.2019.12.049","article-title":"Outcomes in intermediate-risk squamous cell carcinomas treated with Mohs micrographic surgery compared with wide local excision","volume":"82","author":"Xiong","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.113252_bib42","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jaad.2022.06.1169","article-title":"Clinical outcomes of high-risk cutaneous squamous cell carcinomas treated with Mohs micrographic surgery alone: an analysis of local recurrence, regional nodal metastases, progression-free survival, and disease-specific death","volume":"88","author":"Soleymani","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.113252_bib43","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1245\/s10434-022-11669-z","article-title":"Benchmarking survival outcomes following surgical management of pT3 and pT4 cutaneous squamous cell carcinoma of the head and neck","volume":"29","author":"Yung","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2023.113252_bib44","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/DSS.0000000000003462","article-title":"Complete margin assessment versus sectional assessment in surgically excised high-risk keratinocyte carcinomas: a systematic review and meta-analysis","volume":"48","author":"Fraga","year":"2022","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.ejca.2023.113252_bib45","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jaad.2021.07.059","article-title":"Cost-effectiveness of intermediate-risk squamous cell carcinoma treated with Mohs micrographic surgery compared with wide local excision","volume":"86","author":"Udkoff","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.113252_bib46","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/j.1524-4725.2009.01095.x","article-title":"Surgical monotherapy versus surgery plus adjuvant radiotherapy in high-risk cutaneous squamous cell carcinoma: a systematic review of outcomes","volume":"35","author":"Jambusaria-Pahlajani","year":"2009","journal-title":"Dermatol Surg"},{"issue":"5","key":"10.1016\/j.ejca.2023.113252_bib47","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1097\/01.MLG.0000158349.64337.ED","article-title":"Surgery and adjuvant radiotherapy in patients with cutaneous head and neck squamous cell carcinoma metastatic to lymph nodes: combined treatment should be considered best practice","volume":"115","author":"Veness","year":"2005","journal-title":"Laryngoscope"},{"key":"10.1016\/j.ejca.2023.113252_bib48","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1001\/jamaoto.2018.4515","article-title":"Outcomes of cutaneous squamous cell carcinoma in the head and neck region with regional lymph node metastasis: a systematic review and meta-analysis","volume":"145","author":"Sahovaler","year":"2019","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.ejca.2023.113252_bib49","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.bjoms.2014.01.015","article-title":"Management of regional metastatic disease in head and neck cutaneous malignancy. 1. Cutaneous squamous cell carcinoma","volume":"52","author":"Gurney","year":"2014","journal-title":"Br J Oral Maxillofac Surg"},{"key":"10.1016\/j.ejca.2023.113252_bib50","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/MOO.0b013e328343e811","article-title":"Management of the neck in metastatic cutaneous squamous cell carcinoma of the head and neck","volume":"19","author":"D'Souza","year":"2011","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.ejca.2023.113252_bib51","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/hed.10063","article-title":"Significance of clinical stage, extent of surgery, and pathologic findings in metastatic cutaneous squamous carcinoma of the parotid gland","volume":"24","author":"O'Brien","year":"2002","journal-title":"Head Neck"},{"key":"10.1016\/j.ejca.2023.113252_bib52","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/hed.20417","article-title":"Patterns of lymph node spread of cutaneous squamous cell carcinoma of the head and neck","volume":"28","author":"Vauterin","year":"2006","journal-title":"Head Neck"},{"key":"10.1016\/j.ejca.2023.113252_bib53","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/hed.21574","article-title":"Outcome of patients treated surgically for lymph node metastases from cutaneous squamous cell carcinoma of the head and neck","volume":"33","author":"Givi","year":"2011","journal-title":"Head Neck"},{"key":"10.1016\/j.ejca.2023.113252_bib54","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/hed.21332","article-title":"Predicting the pattern of regional metastases from cutaneous squamous cell carcinoma of the head and neck based on location of the primary","volume":"32","author":"Ebrahimi","year":"2010","journal-title":"Head Neck"},{"key":"10.1016\/j.ejca.2023.113252_bib55","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1053\/ejso.2002.1330","article-title":"Treatment results of regional metastasis from cutaneous head and neck squamous cell carcinoma","volume":"29","author":"Jol","year":"2003","journal-title":"Eur J Surg Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.ejca.2023.113252_bib56","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1017\/S0022215112002101","article-title":"In patients with metastatic cutaneous head and neck squamous cell carcinoma to cervical lymph nodes, the extent of neck dissection does not influence outcome","volume":"127","author":"Wang","year":"2013","journal-title":"J Laryngol Otol"},{"key":"10.1016\/j.ejca.2023.113252_bib57","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jaad.2017.10.007","article-title":"Guidelines of care for the management of cutaneous squamous cell carcinoma","volume":"78","author":"Work","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.113252_bib58","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1002\/hed.23843","article-title":"Outcomes of nodal metastatic cutaneous squamous cell carcinoma of the head and neck treated in a regional center","volume":"37","author":"Schmidt","year":"2015","journal-title":"Head Neck"},{"key":"10.1016\/j.ejca.2023.113252_bib59","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/hed.20048","article-title":"Cutaneous metastatic squamous cell carcinoma to the parotid gland: analysis and outcome","volume":"26","author":"Audet","year":"2004","journal-title":"Head Neck"},{"key":"10.1016\/j.ejca.2023.113252_bib60","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ejso.2018.01.003","article-title":"Selective neck dissection in surgically treated head and neck squamous cell carcinoma patients with a clinically positive neck: systematic review","volume":"44","author":"Rodrigo","year":"2018","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejca.2023.113252_bib61","doi-asserted-by":"crossref","DOI":"10.5826\/dpc.11S2a167S","article-title":"Surgery for cutaneous squamous cell carcinoma and its limits in advanced disease","volume":"11","author":"Moreno-Ramirez","year":"2021","journal-title":"Dermatol Pract Concept"},{"key":"10.1016\/j.ejca.2023.113252_bib62","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJMoa2209813","article-title":"Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma","volume":"387","author":"Gross","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.113252_bib63","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/hed.25561","article-title":"Elective neck dissection in metastatic cutaneous squamous cell carcinoma to the parotid gland: a systematic review and meta-analysis","volume":"41","author":"Rotman","year":"2019","journal-title":"Head Neck"},{"key":"10.1016\/j.ejca.2023.113252_bib64","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jaad.2017.04.1108","article-title":"Efficacy of curettage alone for invasive cutaneous squamous cell carcinoma: a retrospective cohort study","volume":"77","author":"Yakish","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.113252_bib65","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jaad.2021.07.067","article-title":"Efficacy of non-excisional treatment modalities for superficially invasive and in situ squamous cell carcinoma: a systematic review and meta-analysis","volume":"87","author":"Stewart","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.113252_bib66","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jaad.2017.10.007","article-title":"Guidelines of care for the management of basal cell carcinoma","volume":"78","author":"Alam","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.113252_bib67","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1111\/jdv.16017","article-title":"European Dermatology Forum guidelines on topical photodynamic therapy 2019 part 1: treatment delivery and established indications - actinic keratoses, Bowen's disease and basal cell carcinomas","volume":"33","author":"Morton","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2023.113252_bib68","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/jdv.16044","article-title":"European Dermatology Forum guidelines on topical photodynamic therapy 2019 part 2: emerging indications - field cancerization, photorejuvenation and inflammatory\/infective dermatoses","volume":"34","author":"Morton","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2023.113252_bib69","article-title":"A review of the literature of surgical and non-surgical treatments of invasive squamous cells carcinoma","volume":"2018","author":"Potenza","year":"2018","journal-title":"BioMed\u00a0Res Int"},{"key":"10.1016\/j.ejca.2023.113252_bib70","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.jaad.2020.12.049","article-title":"Intralesional 5-fluorouracil for the treatment of squamous cell carcinomas","volume":"84","author":"Maxfield","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.113252_bib71","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S0190-9622(80)80007-7","article-title":"Successful treatment of keratoacanthoma with intralesional fluorouracil","volume":"2","author":"Goette","year":"1980","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.113252_bib72","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jaad.2006.12.017","article-title":"Intralesional methotrexate treatment for keratoacanthoma tumours: a retrospective study and review of the literature","volume":"56","author":"Annest","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.113252_bib73","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1111\/bjd.15225","article-title":"An 18-year retrospective study on the outcomes of keratoacanthomas with different treatment modalities at a single academic centre","volume":"177","author":"Tran","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2023.113252_bib74","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/1754-9485.12718","article-title":"Efficacy of hypofractionated radiotherapy in patients with non-melanoma skin cancer: results of a systematic review","volume":"62","author":"Gunaratne","year":"2018","journal-title":"J Med Imaging Radiat Oncol"},{"key":"10.1016\/j.ejca.2023.113252_bib75","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1684\/ejd.2013.2106","article-title":"Post radiation skin tumours: basal cell carcinomas, squamous cell carcinomas and angiosarcomas. A review of this late effect of radiotherapy","volume":"23","author":"Cuperus","year":"2013","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.ejca.2023.113252_bib76","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.fsc.2018.08.005","article-title":"Radiotherapy for skin cancers of the face, head, and neck","volume":"27","author":"Mierzwa","year":"2019","journal-title":"Facial Plast Surg Clin North Am"},{"key":"10.1016\/j.ejca.2023.113252_bib77","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/ajd.13025","article-title":"The role of radiotherapy in the management of non-melanoma skin cancer","volume":"60","author":"Garbutcheon-Singh","year":"2019","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.ejca.2023.113252_bib78","first-page":"641","article-title":"Head and Neck Cancer International Group (HNCIG) consensus guidelines for the delivery of postoperative radiation therapy in complex Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)","volume":"107","author":"Porceddu","year":"2020","journal-title":"Int\u00a0J\u00a0Radiat\u00a0Oncol\u00a0Biol\u00a0Phys"},{"key":"10.1016\/j.ejca.2023.113252_bib79","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1111\/bjd.15728","article-title":"Outcomes of radiation therapy for advanced T3\/T4 non-melanoma cutaneous squamous cell and basal cell carcinoma","volume":"178","author":"Kim","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2023.113252_bib80","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/coa.12707","article-title":"Local control of 151 head and neck cutaneous squamous cell carcinoma after radiotherapy: a retrospective study on efficacy and prognostic factors","volume":"42","author":"Terra","year":"2017","journal-title":"Clin Otolaryngol"},{"key":"10.1016\/j.ejca.2023.113252_bib81","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1001\/jamaoto.2018.3650","article-title":"Association of adjuvant radiation therapy with survival in patients with advanced cutaneous squamous cell carcinoma of the head and neck","volume":"145","author":"Harris","year":"2019","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.ejca.2023.113252_bib82","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/j.ejca.2015.06.110","article-title":"Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline","volume":"51","author":"Stratigos","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.113252_bib83","first-page":"ed2022","article-title":"National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology","author":"Schmults","year":"2022","journal-title":"Squamous\u00a0Cell\u00a0Skin\u00a0Cancer. version 2"},{"key":"10.1016\/j.ejca.2023.113252_bib84","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1097\/DSS.0000000000001827","article-title":"Outcomes of adjuvant radiotherapy following negative surgical margins for cutaneous squamous cell carcinoma","volume":"45","author":"Miller","year":"2019","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.ejca.2023.113252_bib85","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/bjd.17244","article-title":"Local recurrence and quality of life after adjuvant radiation therapy in high-risk squamous cell carcinoma","volume":"180","author":"Yan","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2023.113252_bib86","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0190-9622(94)70073-7","article-title":"Adjuvant radiotherapy after excision of cutaneous squamous cell carcinoma","volume":"30","author":"Geohas","year":"1994","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.113252_bib87","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1002\/cncr.21898","article-title":"High-risk cutaneous squamous cell carcinoma of the head and neck: results from 266 treated patients with metastatic lymph node disease","volume":"106","author":"Veness","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2023.113252_bib88","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/cncr.22509","article-title":"What is the role of adjuvant radiotherapy in the treatment of cutaneous squamous cell carcinoma with perineural invasion?","volume":"109","author":"Han","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2023.113252_bib89","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/jdv.16001","article-title":"Postoperative radiotherapy provides better local control and long-term outcome in selective cases of cutaneous squamous cell carcinoma with perineural invasion","volume":"34","author":"Canueto","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2023.113252_bib90","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.jaad.2021.11.059","article-title":"Adjuvant radiotherapy may not significantly change outcomes in high-risk cutaneous squamous cell carcinomas with clear surgical margins: a systematic review and meta-analysis","volume":"86","author":"Kim","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.113252_bib91","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.jaad.2021.01.063","article-title":"Factors predicting outcomes of patients with high-risk squamous cell carcinoma treated with Mohs micrographic surgery","volume":"85","author":"Matsumoto","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.113252_bib92","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jaad.2019.07.048","article-title":"Evaluation of the utility of localized adjuvant radiation for node-negative primary cutaneous squamous cell carcinoma with clear histologic margins","volume":"82","author":"Ruiz","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.113252_bib93","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1111\/jdv.17330","article-title":"Efficacy and prognostic factors of adjuvant radiotherapy for cutaneous squamous cell carcinoma: a systematic review and meta-analysis","volume":"35","author":"Zhang","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2023.113252_bib94","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jaad.2022.03.044","article-title":"Adjuvant radiation following clear margin resection of high T-stage cutaneous squamous cell carcinoma halves the risk of local and locoregional recurrence: a dual-center retrospective study","volume":"87","author":"Ruiz","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.113252_bib95","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.prro.2019.10.014","article-title":"Definitive and postoperative radiation therapy for basal and squamous cell cancers of the skin: executive summary of an American society for radiation oncology clinical practice guideline","volume":"10","author":"Likhacheva","year":"2020","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ejca.2023.113252_bib96","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.2017.77.0941","article-title":"Postoperative concurrent chemoradiotherapy versus postoperative radiotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck: the randomized phase III TROG 05.01 trial","volume":"36","author":"Porceddu","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113252_bib97","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1002\/hed.21965","article-title":"Predictors of outcome in patients with metastatic cutaneous head and neck squamous cell carcinoma involving cervical lymph nodes: improved survival with the addition of adjuvant radiotherapy","volume":"34","author":"Wang","year":"2012","journal-title":"Head Neck"},{"key":"10.1016\/j.ejca.2023.113252_bib98","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/jdv.18036","article-title":"Outcome of cutaneous squamous cell carcinoma with microscopic residual disease after surgery and usefulness of postoperative radiotherapy: a retrospective cohort study","volume":"36","author":"Revelles-Penas","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2023.113252_bib99","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.113252_bib100","first-page":"1275","article-title":"Phase 1 study of erlotinib plus radiation therapy in patients with advanced cutaneous squamous cell carcinoma","volume":"85","author":"Heath","year":"2013","journal-title":"Int\u00a0J\u00a0Radiat\u00a0Oncol\u00a0Biol\u00a0Phys"},{"key":"10.1016\/j.ejca.2023.113252_bib101","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2006.05.9873","article-title":"Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma","volume":"25","author":"Brewster","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113252_bib102","article-title":"Role of concurrent systemic therapy with adjuvant radiation therapy for locally advanced cutaneous head and neck squamous cell carcinoma","volume":"9","author":"Goyal","year":"2017","journal-title":"Cureus"},{"key":"10.1016\/j.ejca.2023.113252_bib103","first-page":"102","article-title":"Combination of post-operative radiotherapy and cetuximab for high-risk cutaneous squamous cell cancer of the head and neck: a propensity score analysis","volume":"78","author":"Palmer","year":"2018","journal-title":"Oral\u00a0Oncol"},{"key":"10.1016\/j.ejca.2023.113252_bib104","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1002\/hed.26835","article-title":"Adjuvant radiation and cetuximab improves local control in head and neck cutaneous squamous cell carcinoma: phase II study","volume":"43","author":"Kreinbrink","year":"2021","journal-title":"Head Neck"},{"key":"10.1016\/j.ejca.2023.113252_bib105","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/jdv.13266","article-title":"Neoadjuvant intralesional methotrexate in cutaneous squamous cell carcinoma: a comparative cohort study","volume":"30","author":"Salido-Vallejo","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2023.113252_bib106","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/bjd.13741","article-title":"Efficacy of neoadjuvant cetuximab alone or with platinum salt for the treatment of unresectable advanced non-metastatic cutaneous squamous cell carcinomas","volume":"173","author":"Reigneau","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2023.113252_bib107","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2015-000003","article-title":"A prospective clinical trial to assess lapatinib effects on cutaneous squamous cell carcinoma and actinic keratosis","volume":"1","author":"Jenni","year":"2016","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2023.113252_bib108","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1158\/1078-0432.CCR-11-1951","article-title":"A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck","volume":"18","author":"Lewis","year":"2012","journal-title":"Clin\u00a0Cancer\u00a0Res"},{"key":"10.1016\/j.ejca.2023.113252_bib109","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1158\/1078-0432.CCR-21-0585","article-title":"Pilot phase II trial of neoadjuvant immunotherapy in locoregionally advanced, resectable cutaneous squamous cell carcinoma of the head and neck","volume":"27","author":"Ferrarotto","year":"2021","journal-title":"Clin Cancer\u00a0Res"},{"key":"10.1016\/j.ejca.2023.113252_bib110","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1097\/DSS.0000000000000864","article-title":"In-transit metastasis from squamous cell carcinoma","volume":"42","author":"Ma","year":"2016","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.ejca.2023.113252_bib111","first-page":"651","article-title":"In-transit metastasis from primary cutaneous squamous cell carcinoma in organ transplant recipients and non-immunosuppressed patients: clinical characteristics, management, and outcome in a series of 21 patients","volume":"30","author":"Carucci","year":"2004","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.ejca.2023.113252_bib112","first-page":"270","article-title":"Electrochemotherapy for the management of cutaneous and subcutaneous metastasis: a series of 39 patients treated with palliative intent","volume":"109","author":"Solari","year":"2014","journal-title":"J\u00a0Surg\u00a0Oncol"},{"key":"10.1016\/j.ejca.2023.113252_bib113","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41416-018-0149-z","article-title":"Isolated limb perfusion for unresectable extremity cutaneous squamous cell carcinoma; an effective limb saving strategy","volume":"119","author":"Huis In 't Veld","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2023.113252_bib114","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1080\/02656736.2016.1188999","article-title":"Isolated limb perfusion as a treatment option for rare types of tumours","volume":"32","author":"Belgrano","year":"2016","journal-title":"Int J Hyperthermia"},{"key":"10.1016\/j.ejca.2023.113252_bib115","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.113252_bib116","doi-asserted-by":"crossref","first-page":"6582","DOI":"10.1158\/1078-0432.CCR-14-1768","article-title":"Mutational landscape of aggressive cutaneous squamous cell carcinoma","volume":"20","author":"Pickering","year":"2014","journal-title":"Clin\u00a0Cancer\u00a0Res"},{"key":"10.1016\/j.ejca.2023.113252_bib117","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumour mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.113252_bib118","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jamadermatol.2016.5118","article-title":"Expression of programmed cell death ligand in cutaneous squamous cell carcinoma and treatment of locally advanced disease with pembrolizumab","volume":"153","author":"Stevenson","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2023.113252_bib119","article-title":"Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing","volume":"8","author":"Rischin","year":"2020","journal-title":"J\u00a0Immunother\u00a0Cancer"},{"key":"10.1016\/j.ejca.2023.113252_bib120","article-title":"Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis","volume":"9","author":"Rischin","year":"2021","journal-title":"J\u00a0Immunother\u00a0Cancer"},{"key":"10.1016\/j.ejca.2023.113252_bib121","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S1470-2045(19)30728-4","article-title":"Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial","volume":"21","author":"Migden","year":"2020","journal-title":"Lancet Oncol"},{"issue":"Supplement 7","key":"10.1016\/j.ejca.2023.113252_bib122","first-page":"S918","article-title":"Phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): final analysis from EMPOWER-CSCC-1 groups 1, 2 and 3. Abstract 814P","volume":"33","author":"Migden","year":"2022","journal-title":"Ann\u00a0Oncol"},{"issue":"Supplement 7","key":"10.1016\/j.ejca.2023.113252_bib123","first-page":"S921","article-title":"Phase II confirmatory study of cemiplimab (350mg IV Q3W) in patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): study 1540 group 6. Abstract 818P","volume":"33","author":"Hughes","year":"2022","journal-title":"Ann\u00a0Oncol"},{"key":"10.1016\/j.ejca.2023.113252_bib124","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1200\/JCO.19.03054","article-title":"Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase ii trial (KEYNOTE-629)","volume":"38","author":"Grob","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113252_bib125","first-page":"1276","article-title":"Pembrolizumab for locally advanced and recurrent\/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, non-randomized, multicenter, phase II trial","volume":"32","author":"Hughes","year":"2021","journal-title":"Ann\u00a0Oncol"},{"key":"10.1016\/j.ejca.2023.113252_bib126","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/COC.0000000000000088","article-title":"Systemic therapy in advanced cutaneous squamous cell carcinoma (CSCC): the Roswell Park experience and a review of the literature","volume":"39","author":"Jarkowski","year":"2016","journal-title":"Am J Clin\u00a0Oncol"},{"key":"10.1016\/j.ejca.2023.113252_bib127","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1200\/JCO.19.03357","article-title":"Phase II study of pembrolizumab as first-line, single-drug therapy for patients with unresectable cutaneous squamous cell carcinomas","volume":"38","author":"Maubec","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113252_bib128","first-page":"611","article-title":"Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma","volume":"17","author":"Keeping","year":"2021","journal-title":"Future\u00a0Oncol\u00a0(London, England)"},{"key":"10.1016\/j.ejca.2023.113252_bib129","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejca.2022.03.035","article-title":"Comparative efficacy analysis identifies immune checkpoint blockade as a new survival benchmark in advanced cutaneous squamous cell carcinoma","volume":"170","author":"Petzold","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.113252_bib130","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1007\/s13555-021-00598-6","article-title":"Health-related quality of life of patients with recurrent or metastatic cutaneous squamous cell carcinoma treated with pembrolizumab in KEYNOTE-629","volume":"11","author":"Hughes","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.ejca.2023.113252_bib131","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1111\/bjd.14936","article-title":"Epidermal growth factor receptor expression is associated with poor outcome in cutaneous squamous cell carcinoma","volume":"176","author":"Canueto","year":"2017","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.ejca.2023.113252_bib132","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/jid.2009.312","article-title":"Somatic mutation of epidermal growth factor receptor in a small subset of cutaneous squamous cell carcinoma","volume":"130","author":"Ridd","year":"2010","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ejca.2023.113252_bib133","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1093\/annonc\/mdu368","article-title":"Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma","volume":"25","author":"Foote","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2023.113252_bib134","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/jamadermatol.2015.4134","article-title":"Complete remission of squamous cell carcinoma after treatment with panitumumab in a patient with cetuximab-induced anaphylaxis","volume":"152","author":"Marti","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2023.113252_bib135","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1111\/jdv.16465","article-title":"Efficacy and safety of panitumumab alone or in association with radiotherapy in unresectable cutaneous squamous cell carcinoma","volume":"34","author":"Hourbeigt","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2023.113252_bib136","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jaad.2017.07.048","article-title":"Gefitinib for patients with incurable cutaneous squamous cell carcinoma: a single-arm phase II clinical trial","volume":"77","author":"William","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.113252_bib137","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1002\/cncr.31346","article-title":"Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase 2 clinical trial","volume":"124","author":"Gold","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2023.113252_bib138","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/DSS.0000000000000799","article-title":"Cisplatin and cetuximab treatment for metastatic cutaneous squamous cell carcinoma: a systematic review","volume":"43","author":"Trodello","year":"2017","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.ejca.2023.113252_bib139","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1001\/jamadermatol.2017.0270","article-title":"Association of oncogenic mutations in patients with advanced cutaneous squamous cell carcinomas treated with cetuximab","volume":"153","author":"Picard","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2023.113252_bib140","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000362384","article-title":"Cetuximab in metastatic squamous cell cancer of the skin: a Swiss case series","volume":"229","author":"Conen","year":"2014","journal-title":"Dermatology"},{"key":"10.1016\/j.ejca.2023.113252_bib141","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1200\/JCO.2010.34.1735","article-title":"Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin","volume":"29","author":"Maubec","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113252_bib142","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1159\/000461578","article-title":"Efficacy and tolerance of cetuximab alone or combined with chemotherapy in locally advanced or metastatic cutaneous squamous cell carcinoma: an open study of 14 patients","volume":"232","author":"Dereure","year":"2016","journal-title":"Dermatology"},{"key":"10.1016\/j.ejca.2023.113252_bib143","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.clon.2011.07.007","article-title":"Efficacy of cetuximab for unresectable or advanced cutaneous squamous cell carcinoma\u2013a report of eight cases","volume":"23","author":"Giacchero","year":"2011","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ejca.2023.113252_bib144","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/284582","article-title":"Locally advanced and unresectable cutaneous squamous cell carcinoma: outcomes of concurrent cetuximab and radiotherapy","volume":"2014","author":"Samstein","year":"2014","journal-title":"J Skin Cancer"},{"key":"10.1016\/j.ejca.2023.113252_bib145","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/DSS.0000000000001755","article-title":"Cetuximab as a component of multimodality treatment of high-risk cutaneous squamous cell carcinoma: a retrospective analysis from a single tertiary academic medical center","volume":"45","author":"Trodello","year":"2019","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.ejca.2023.113252_bib146","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/DSS.0000000000001583","article-title":"Response of cutaneous squamous cell carcinoma to treatment with cetuximab","volume":"45","author":"Berliner","year":"2019","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.ejca.2023.113252_bib147","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/1754-9485.12842","article-title":"Cetuximab-radiotherapy combination in the management of locally advanced cutaneous squamous cell carcinoma","volume":"63","author":"Joseph","year":"2019","journal-title":"J Med Imaging Radiat Oncol"},{"key":"10.1016\/j.ejca.2023.113252_bib148","doi-asserted-by":"crossref","first-page":"7381","DOI":"10.1002\/cam4.3146","article-title":"Clinical outcomes among unresectable, locally advanced, and metastatic cutaneous squamous cell carcinoma patients treated with systemic therapy","volume":"9","author":"Cowey","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2023.113252_bib149","first-page":"1935","article-title":"Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck","volume":"59","author":"Huang","year":"1999","journal-title":"Cancer\u00a0Res"},{"key":"10.1016\/j.ejca.2023.113252_bib150","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3109\/09546634.2012.751481","article-title":"Efficacy of cetuximab in the treatment of squamous cell carcinoma","volume":"25","author":"Preneau","year":"2014","journal-title":"J Dermatolog Treat"},{"issue":"Suppl 1","key":"10.1016\/j.ejca.2023.113252_bib151","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/jdv.17404","article-title":"Management of partial and non-responding cutaneous squamous cell carcinoma","volume":"36","author":"Jansen","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2023.113252_bib152","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/CCO.0000000000000359","article-title":"Drug therapy of advanced cutaneous squamous cell carcinoma: is there any evidence?","volume":"29","author":"Ribero","year":"2017","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.ejca.2023.113252_bib153","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1200\/JCO.1990.8.2.342","article-title":"Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy","volume":"8","author":"Guthrie","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113252_bib154","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s00432-004-0656-6","article-title":"Oral capecitabine plus subcutaneous interferon alpha in advanced squamous cell carcinoma of the skin","volume":"131","author":"Wollina","year":"2005","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113252_bib155","first-page":"181","article-title":"Oral 5-fluorouracil in squamous cell carcinoma of the skin in the aged","volume":"23","author":"Cartei","year":"2000","journal-title":"Am\u00a0J Clin\u00a0Oncol"},{"key":"10.1016\/j.ejca.2023.113252_bib156","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1200\/JCO.2002.20.2.364","article-title":"Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer","volume":"20","author":"Shin","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113252_bib157","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1684\/ejd.2012.1845","article-title":"Complete response of metastatic cutaneous squamous cell carcinoma to cetuximab plus paclitaxel","volume":"22","author":"Mecca","year":"2012","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.ejca.2023.113252_bib158","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v101.751","article-title":"Real-world treatment patterns and outcomes with systemic therapies in unresectable locally advanced and metastatic cutaneous squamous cell carcinoma in Germany","volume":"102","author":"Kramb","year":"2022","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ejca.2023.113252_bib159","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1080\/0284186X.2018.1454602","article-title":"Updated standard operating procedures for electrochemotherapy of cutaneous tumours and skin metastases","volume":"57","author":"Gehl","year":"2018","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ejca.2023.113252_bib160","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13547","article-title":"The use of cisplatin electrochemotherapy in non-melanoma skin cancers: a single-center study","volume":"33","author":"De Giorgi","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ejca.2023.113252_bib161","first-page":"470","article-title":"Prospective cohort study by InspECT on safety and efficacy of electrochemotherapy for cutaneous tumours and metastases depending on ulceration","volume":"20","author":"Claussen","year":"2022","journal-title":"J\u00a0Ger\u00a0Soc\u00a0Dermatol: JDDG"},{"key":"10.1016\/j.ejca.2023.113252_bib162","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejca.2020.06.020","volume":"138","author":"Clover","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.113252_bib163","article-title":"Electrochemotherapy for the treatment of cutaneous squamous cell carcinoma: the INSPECT experience (2008\u20132020)","volume":"12","author":"Bertino","year":"2022","journal-title":"Front\u00a0Oncol"},{"key":"10.1016\/j.ejca.2023.113252_bib164","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.ejso.2020.10.037","article-title":"Outcomes of older adults aged 90 and over with cutaneous malignancies after electrochemotherapy with bleomycin: a matched cohort analysis from the InspECT registry","volume":"47","author":"Sersa","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejca.2023.113252_bib165","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJMoa2209813","article-title":"Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma","volume":"387","author":"Gross","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.113252_bib166","article-title":"Updated results from the skin cancer cohorts from an ongoing phase 1\/2 multicohort study of RP1, an enhanced potency oncolytic HSV, combined with nivolumab (IGNYTE). Abstract 9553","volume":"40","author":"Mihem","year":"2022","journal-title":"J\u00a0Clin\u00a0Oncol"},{"key":"10.1016\/j.ejca.2023.113252_bib167","article-title":"Immunotherapy followed by cetuximab in locally advanced\/metastatic (LA\/M) cutaneous squamous cell carcinomas (cSCC): the I-TACKLE trial. Abstract 9520","volume":"40","author":"Bossi","year":"2022","journal-title":"J\u00a0Clin\u00a0Oncol"},{"key":"10.1016\/j.ejca.2023.113252_bib168","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2217\/fon-2019-0762","article-title":"CASE (CemiplimAb-rwlc survivorship and epidemiology) study in advanced cutaneous squamous cell carcinoma","volume":"16","author":"Migden","year":"2020","journal-title":"Future Oncol"},{"key":"10.1016\/j.ejca.2023.113252_bib169","first-page":"S356","article-title":"CemiplimAb-rwlc survivorship and epidemiology (CASE): a prospective study of the safety and efficacy of cemiplimab in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC) in a real-world setting\u00a0825P","volume":"33","author":"Rabinowits","year":"2022","journal-title":"Ann\u00a0Oncol"},{"key":"10.1016\/j.ejca.2023.113252_bib170","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.det.2018.07.009","article-title":"Skin cancer and immunosuppression","volume":"37","author":"Collins","year":"2019","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.ejca.2023.113252_bib171","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-029265","article-title":"Behavioural and pharmaceutical interventions for the prevention of skin cancers in solid organ transplant recipients: a systematic review of randomised controlled trials","volume":"10","author":"James","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.ejca.2023.113252_bib172","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/bjd.15932","article-title":"Organ transplantation and cutaneous squamous cell carcinoma: progress, pitfalls and priorities in immunosuppression-associated keratinocyte carcinoma","volume":"177","author":"Harwood","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2023.113252_bib173","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1111\/bjd.15950","article-title":"Research gaps in the management and prevention of cutaneous squamous cell carcinoma in organ transplant recipients","volume":"177","author":"Blomberg","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2023.113252_bib174","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/ajt.13593","volume":"16","author":"Zwald","year":"2016","journal-title":"Am\u00a0J Transplant"},{"key":"10.1016\/j.ejca.2023.113252_bib175","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s11864-012-0195-3","article-title":"Management of non-melanoma skin cancer in immunocompromised solid organ transplant recipients","volume":"13","author":"Bangash","year":"2012","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.ejca.2023.113252_bib176","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1097\/DSS.0000000000003085","article-title":"Sentinel lymph node biopsy in high-risk cutaneous squamous cell carcinoma: analysis of a large size retrospective series","volume":"47","author":"Tremblay-Abel","year":"2021","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.ejca.2023.113252_bib177","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.amjoto.2013.08.014","article-title":"Utility of positron emission tomography\/computed tomography for nodal staging of cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia","volume":"35","author":"Tomaszewski","year":"2014","journal-title":"Am J Otolaryngol"},{"issue":"Suppl 8","key":"10.1016\/j.ejca.2023.113252_bib178","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/jdv.15843","article-title":"Treatment approaches in immunosuppressed patients with advanced cutaneous squamous cell carcinoma","volume":"33","author":"Willenbrink","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2023.113252_bib179","first-page":"642","article-title":"Guidelines for the management of squamous cell carcinoma in organ transplant recipients","volume":"30","author":"Stasko","year":"2004","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.ejca.2023.113252_bib180","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/DSS.0000000000001645","article-title":"Association of postoperative antibiotics with surgical site infection in Mohs micrographic surgery","volume":"45","author":"Levin","year":"2019","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.ejca.2023.113252_bib181","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/00042728-200802000-00011","article-title":"The effects of sirolimus on wound healing in dermatologic surgery","volume":"34","author":"Brewer","year":"2008","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.ejca.2023.113252_bib182","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1111\/ajt.14238","article-title":"Chemotherapy and transplantation: the role of immunosuppression in malignancy and a review of antineoplastic agents in solid organ transplant recipients","volume":"17","author":"Krisl","year":"2017","journal-title":"Am J\u00a0Transplant"},{"key":"10.1016\/j.ejca.2023.113252_bib183","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s10354-013-0213-5","article-title":"Cetuximab for treatment of advanced squamous cell carcinoma in solid organ transplant recipients","volume":"163","author":"Boyd","year":"2013","journal-title":"Wien Med Wochenschr"},{"key":"10.1016\/j.ejca.2023.113252_bib184","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1200\/JCO.2013.49.2314","article-title":"Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma","volume":"32","author":"Lipson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113252_bib185","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejca.2018.01.075","article-title":"Advanced cutaneous squamous cell carcinoma: a retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG","volume":"96","author":"Hillen","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.113252_bib186","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.healun.2007.09.019","article-title":"Fatal diffuse alveolar damage in two lung transplant patients treated with cetuximab","volume":"26","author":"Leard","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.ejca.2023.113252_bib187","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S1470-2045(22)00368-0","article-title":"Immune checkpoint inhibitors in kidney transplant recipients: a multicentre, single-arm, phase 1 study","volume":"23","author":"Carroll","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.113252_bib188","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMc1509268","article-title":"Tumour regression and allograft rejection after administration of anti-PD-1","volume":"374","author":"Lipson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.113252_bib189","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejca.2018.09.017","article-title":"Anti-PD-1\/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B\/C infection","volume":"104","author":"Tio","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.113252_bib190","first-page":"54","article-title":"Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go?","volume":"31","author":"De Bruyn","year":"2019","journal-title":"Curr\u00a0Opin\u00a0Oncol"},{"key":"10.1016\/j.ejca.2023.113252_bib191","article-title":"Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature","volume":"7","author":"Abdel-Wahab","year":"2019","journal-title":"J\u00a0Immunother\u00a0Cancer"},{"key":"10.1016\/j.ejca.2023.113252_bib192","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.jaad.2019.07.005","article-title":"Immune checkpoint inhibitor therapy in solid organ transplant recipients: a patient-centered systematic review","volume":"82","author":"Fisher","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.113252_bib193","first-page":"2457","article-title":"Efficacy and tolerance of immune checkpoint inhibitors in transplant patients with cancer: a systematic review","volume":"20","author":"d'Izarny-Gargas","year":"2020","journal-title":"Am\u00a0J\u00a0Transplant"},{"key":"10.1016\/j.ejca.2023.113252_bib194","article-title":"Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients","volume":"8","author":"Leiter","year":"2020","journal-title":"J\u00a0Immunother\u00a0Cancer"},{"key":"10.1016\/j.ejca.2023.113252_bib195","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1038\/s41416-020-01044-8","article-title":"Real-world outcomes treating patients with advanced cutaneous squamous cell carcinoma with immune checkpoint inhibitors (CPI)","volume":"123","author":"Hanna","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2023.113252_bib196","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1634\/theoncologist.2019-0659","article-title":"The safety and efficacy of checkpoint inhibitors in transplant recipients: a case series and systematic review of literature","volume":"25","author":"Kumar","year":"2020","journal-title":"Oncologist"},{"issue":"Suppl 1","key":"10.1016\/j.ejca.2023.113252_bib197","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/jdv.17407","article-title":"Treatment of metastatic cutaneous squamous cell carcinoma in a solid organ transplant recipient with programmed death-1 checkpoint inhibitor therapy","volume":"36","author":"O'Connell","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2023.113252_bib198","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1097\/TP.0000000000004459","article-title":"Immune checkpoint inhibitors in solid organ transplant recipients with advanced skin cancers-emerging strategies for clinical management","volume":"107","author":"Ferrandiz-Pulido","year":"2023","journal-title":"Transplantation"},{"key":"10.1016\/j.ejca.2023.113252_bib199","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1634\/theoncologist.2018-0195","article-title":"Immune checkpoint inhibitors and the risk of allograft rejection: a comprehensive analysis on an emerging issue","volume":"24","author":"Aguirre","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2023.113252_bib200","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1200\/JOP.19.00567","article-title":"Successful administration of cemiplimab to a patient with advanced cutaneous squamous cell carcinoma after renal transplantation","volume":"16","author":"Ali","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.ejca.2023.113252_bib201","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/onco.13539","article-title":"A pilot study of checkpoint inhibitors in solid organ transplant recipients with metastatic cutaneous squamous cell carcinoma","volume":"26","author":"Tsung","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2023.113252_bib202","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3390\/curroncol28010057","article-title":"Safe administration of cemiplimab to a kidney transplant patient with locally advanced squamous cell carcinoma of the scalp","volume":"28","author":"Paoluzzi","year":"2021","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ejca.2023.113252_bib203","first-page":"3065","article-title":"Ipilimumab for the treatment of advanced melanoma in six kidney transplant patients","volume":"18","author":"Zehou","year":"2018","journal-title":"Am\u00a0J\u00a0Transplant"},{"issue":"2","key":"10.1016\/j.ejca.2023.113252_bib204","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1056\/NEJMc1614298","article-title":"Preserved renal-allograft function and the PD-1 pathway inhibitor nivolumab","volume":"376","author":"Barnett","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.113252_bib205","article-title":"Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation","volume":"10","author":"Esfahani","year":"2019","journal-title":"Nat\u00a0Commun"},{"key":"10.1016\/j.ejca.2023.113252_bib206","first-page":"2264","article-title":"Kidney retransplantation after anti-programmed cell death-1 (PD-1)-related allograft rejection","volume":"20","author":"Lipson","year":"2020","journal-title":"Am\u00a0J\u00a0Transplant"},{"key":"10.1016\/j.ejca.2023.113252_bib207","first-page":"119","article-title":"A surveillance model for skin cancer in organ transplant recipients: a 22-year prospective study in an ethnically diverse population","volume":"13","author":"Harwood","year":"2013","journal-title":"Am\u00a0J\u00a0Transplant"},{"key":"10.1016\/j.ejca.2023.113252_bib208","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1097\/TP.0000000000001644","article-title":"Risk of aggressive skin cancers after kidney retransplantation in patients with previous posttransplant cutaneous squamous cell carcinomas: a retrospective study of 53 cases","volume":"101","author":"Ducroux","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.ejca.2023.113252_bib209","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2016.05.001","article-title":"European research on electrochemotherapy in head and neck cancer (EURECA) project: results of the treatment of skin cancer","volume":"63","author":"Bertino","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.113252_bib210","doi-asserted-by":"crossref","first-page":"165","DOI":"10.21037\/apm.2016.11.10","article-title":"Palliative radiotherapy for skin malignancies","volume":"6","author":"Vuong","year":"2017","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.ejca.2023.113252_bib211","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.21037\/apm-22-228","article-title":"Single-fraction high-dose palliative radiotherapy for facial cutaneous squamous cell carcinoma: a case report","volume":"11","author":"McLaughlin","year":"2022","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.ejca.2023.113252_bib212","unstructured":"World Health Organization (WHO). Palliative care. https:\/\/www.who.int\/health-topics\/palliative-care [accessed\u00a010 October,\u00a02022]."},{"key":"10.1016\/j.ejca.2023.113252_bib213","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/SPC.0000000000000261","article-title":"Pain prevalence in cancer patients: status quo or opportunities for improvement?","volume":"11","author":"Haumann","year":"2017","journal-title":"Curr Opin Support Palliat Care"},{"key":"10.1016\/j.ejca.2023.113252_bib214","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2147\/JPR.S97759","article-title":"Effectiveness of the World Health Organization cancer pain relief guidelines: an integrative review","volume":"9","author":"Carlson","year":"2016","journal-title":"J Pain Res"},{"key":"10.1016\/j.ejca.2023.113252_bib215","doi-asserted-by":"crossref","first-page":"146","DOI":"10.5114\/aoms.2018.72566","article-title":"Topical morphine for treatment of cancer-related painful mucosal and cutaneous lesions: a double-blind, placebo-controlled cross-over clinical trial","volume":"15","author":"Cialkowska-Rysz","year":"2019","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.ejca.2023.113252_bib216","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1200\/JCO.18.00794","article-title":"Follow-up of patients with complete remission of locally advanced basal cell carcinoma after vismodegib discontinuation: a multicenter french study of 116 patients","volume":"37","author":"Herms","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113252_bib217","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1053\/ejso.1999.0931","article-title":"Educational tips in the treatment of malignant ulcerating tumours of the skin","volume":"26","author":"van Leeuwen","year":"2000","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejca.2023.113252_bib218","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.3390\/cancers14051203","article-title":"Treatment algorithm for cancerous wounds: a systematic review","volume":"14","author":"Furka","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejca.2023.113252_bib219","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/01.ASW.0000383206.32244.e2","article-title":"Local wound care for malignant and palliative wounds","volume":"23","author":"Woo","year":"2010","journal-title":"Adv Skin Wound Care"},{"key":"10.1016\/j.ejca.2023.113252_bib220","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1200\/JCO.22.01357","article-title":"Integrative medicine for pain management in oncology: society for integrative oncology-ASCO guideline","volume":"40","author":"Mao","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113252_bib221","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-022-10213-2","article-title":"A nomogram combining clinical factors and biomarkers for predicting the recurrence of high-risk cutaneous squamous cell carcinoma","volume":"22","author":"Oh","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2023.113252_bib222","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/hed.27233","article-title":"Impact of AJCC 8 pT staging in cutaneous head and neck squamous cell carcinoma in a non-selected real-world patient sample","volume":"45","author":"Girardi","year":"2023","journal-title":"Head Neck"},{"key":"10.1016\/j.ejca.2023.113252_bib223","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1001\/jamadermatol.2022.4590","article-title":"Follow-up of patients with keratinocyte carcinoma: a systematic review of clinical practice guidelines","volume":"159","author":"Mirali","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2023.113252_bib224","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/bjd.20974","article-title":"Topical treatment of actinic keratoses in organ transplant recipients: a feasibility study for SPOT (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments)","volume":"187","author":"Hasan","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2023.113252_bib225","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1001\/jamadermatol.2022.1034","article-title":"Risk of invasive cutaneous squamous cell carcinoma after different treatments for actinic keratosis: a secondary analysis of a randomized clinical trial","volume":"158","author":"Ahmady","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2023.113252_bib226","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000525974","article-title":"Influence of frailty and life expectancy on guideline adherence and outcomes in cutaneous squamous cell carcinoma of the head and neck: a prospective pilot study","volume":"239","author":"Leus","year":"2023","journal-title":"Dermatology"},{"key":"10.1016\/j.ejca.2023.113252_bib227","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/bjd.21250","article-title":"Risk factors for distant metastasis in cutaneous squamous cell carcinoma","volume":"187","author":"Stefanovic","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2023.113252_bib228","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.amjoto.2017.01.035","article-title":"Rate of regional nodal metastases of cutaneous squamous cell carcinoma in the immunosuppressed patient","volume":"38","author":"McLaughlin","year":"2017","journal-title":"Am J Otolaryngol"},{"key":"10.1016\/j.ejca.2023.113252_bib229","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1001\/jamadermatol.2015.1702","article-title":"Outcomes of patients with multiple cutaneous squamous cell carcinomas: a 10-year single-institution cohort study","volume":"151","author":"Levine","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2023.113252_bib230","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/jamadermatol.2017.4506","article-title":"Cutaneous squamous cell carcinomas in solid organ transplant recipients compared with immunocompetent patients","volume":"154","author":"Cheng","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2023.113252_bib231","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/bjd.16900","article-title":"Needs and preferences of patients regarding basal cell carcinoma and cutaneous squamous cell carcinoma care: a qualitative focus group study","volume":"180","author":"van Egmond","year":"2019","journal-title":"Br J Dermatol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923003544?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923003544?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:41:35Z","timestamp":1760733695000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923003544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":231,"alternative-id":["S0959804923003544"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113252","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment\u2013Update 2023","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113252","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"113252"}}